BioCryst Pharmaceuticals — Third Quarter 2026 Earnings Summary

BioCryst Pharmaceuticals reported third-quarter 2026 total net revenue of $180.3 million, driven by $174.8 million in ORLADEYO sales. The company achieved an operating profit of $53.3 million and a non-GAAP operating profit of $86.5 million, while maintaining full-year ORLADEYO revenue guidance between $625 million and $645 million. Regulatory progress included FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older, alongside a strategic transition to CareMed as its sole specialty pharmacy partner. Additionally, the company updated its full-year 2026 total revenue outlook to $715 million to $730 million and improved its non-GAAP operating expense guidance to $415 million to $425 million.